

**Beneficiary Information**

1. Beneficiary Last Name: \_\_\_\_\_ 2. First Name: \_\_\_\_\_  
3. Beneficiary ID #: \_\_\_\_\_ 4. Beneficiary Date of Birth: \_\_\_\_\_ 5. Beneficiary Gender: \_\_\_\_\_

**Prescriber Information**

6. Prescriber Name: \_\_\_\_\_ NPI #: \_\_\_\_\_  
Mailing address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_  
7. Requester Contact Information: \_\_\_\_\_  
Name: \_\_\_\_\_ Phone #: \_\_\_\_\_ Fax #: \_\_\_\_\_

**Drug Information**

8. Drug Name: \_\_\_\_\_ 9. Strength: \_\_\_\_\_ 10. Quantity Per 30 Days: \_\_\_\_\_  
11. Length of Therapy : Initial Authorization: \_\_\_up to 30 days \_\_\_60 days \_\_\_90 days  
Reauthorization: \_\_\_up to 30 days \_\_\_60 days \_\_\_90 days \_\_\_120 days \_\_\_180 days

**Clinical Information**

1. Is the beneficiary age 18 or older? Yes\_\_\_ No\_\_\_
2. Does the beneficiary have an adequate documented trial and failure of, or contraindication to, at least one preferred drug in the Anti-Narcolepsy class on the NC PDL?  
Yes\_\_\_ No\_\_\_ Please explain if contraindicated: \_\_\_\_\_
3. Does the beneficiary have a diagnosis of obstructive sleep apnea (OSA)? Yes\_\_\_ No\_\_\_
4. Does the beneficiary have a diagnosis of narcolepsy? Yes\_\_\_ No\_\_\_
5. Does the beneficiary have end stage renal disease (estimated glomerular filtration rate [eGFR] < 15ml/min/1.73m2)?  
Yes\_\_\_ No\_\_\_
6. Has the beneficiary had blood pressure assessed and hypertension controlled (<= 140/90 mmHg) prior to initiating treatment?  
Yes\_\_\_ No\_\_\_
7. Has the beneficiary received an MAO inhibitor within the previous 14 days? Yes\_\_\_ No\_\_\_
8. Is the beneficiary receiving concomitant noradrenergic medications? Yes\_\_\_ No\_\_\_
9. If using to treat OSA, does the provider attest that the beneficiary is compliant with and will continue using positive airway pressure (PAP)? Yes\_\_\_ No\_\_\_
10. If using to treat OSA, has the prescriber excluded any other identifiable causes for beneficiary's sleepiness (e.g. non-compliance with PAP, improperly fitted AP mask, insufficient sleep, poor sleep hygiene, depression, and/or other sleep disorders)? Yes\_\_\_ No\_\_\_

**For continuation of therapy, please answer questions 1-13**

12. Has the beneficiary developed increased blood pressure or heart rate that was not controlled by dose reduction of solriamfetol (Sunosi) or medical intervention? Yes\_\_\_ No\_\_\_
13. Has the beneficiary reported a documented reduction in excessive daytime sleepiness from pre-treatment baseline as measured by a validated scale (e.g., Epworth Sleepiness Scale, Stanford Sleepiness Scale, Karolinska Sleepiness Scale, Cleveland Adolescent Sleepiness Questionnaire, or a Visual Analog Scale)? Yes\_\_\_ No\_\_\_

Signature of Prescriber: \_\_\_\_\_

Date: \_\_\_\_\_

**\*Prescriber signature mandatory**

I certify that the information provided is accurate and complete to the best of my knowledge, and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.